NUREXONE BIOLOGIC INC.NUREXONE BIOLOGIC INC.NUREXONE BIOLOGIC INC.

NUREXONE BIOLOGIC INC.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪27.06 M‬EUR
−0.065EUR
‪−3.36 M‬EUR
0.00EUR
‪47.44 M‬
Beta (1Y)
−1.25

About NUREXONE BIOLOGIC INC


CEO
Lior Shaltiel
Headquarters
Bnei-Brak
Founded
2011
FIGI
BBG00H90W3P3
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. It focuses on the treatment of spinal cord injury, traumatic brain injury, and other brain and neurological indications. The company was founded on June 27, 2011 and is headquartered in Bnei-Brak, Israel.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NUREXONE BIOLOGIC INC. stocks are traded under the ticker J90.
We've gathered analysts' opinions on NUREXONE BIOLOGIC INC. future price: according to them, J90 price has a max estimate of 2.04 EUR and a min estimate of 2.04 EUR. Watch J90 chart and read a more detailed NUREXONE BIOLOGIC INC. stock forecast: see what analysts think of NUREXONE BIOLOGIC INC. and suggest that you do with its stocks.
J90 reached its all-time high on Feb 19, 2024 with the price of 0.920 EUR, and its all-time low was 0.105 EUR and was reached on Sep 21, 2023. View more price dynamics on J90 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track NUREXONE BIOLOGIC INC. financials in yearly and quarterly reports right on TradingView.
NUREXONE BIOLOGIC INC. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
J90 earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.03 EUR resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.02 EUR per share. See more details about NUREXONE BIOLOGIC INC. earnings.
NUREXONE BIOLOGIC INC. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
J90 net income for the last quarter is ‪−1.13 M‬ EUR, while the quarter before that showed ‪−1.24 M‬ EUR of net income which accounts for 8.49% change. Track more NUREXONE BIOLOGIC INC. financial stats to get the full picture.
No, J90 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 13, 2024, the company has 17.00 employees. See our rating of the largest employees — is NUREXONE BIOLOGIC INC. on this list?
Like other stocks, J90 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NUREXONE BIOLOGIC INC. stock right from TradingView charts — choose your broker and connect to your account.